{
  "source": "PA-Notification-Krazati.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1404-3\nProgram Prior Authorization/Notification\nMedication Krazati™ (adagrasib)\nP&T Approval Date 2/2023, 2/2024, 8/2024\nEffective Date 11/1/2024\n1. Background:\nKrazati™ (adagrasib) is an inhibitor of the RAS GTPase family indicated for as a single agent, for\nthe treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-\nsmall cell lung cancer (NSCLC) who have received at least one prior systemic therapy. Krazati is\nalso indicated in combination with cetuximab, for the treatment of adult patients with KRAS\nG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior\ntreatment with fluorpyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.\nThe National Comprehensive Cancer Network (NCCN) recommends the use of Krazati as a\nsingle agent for the treatment of KRAS G12C mutation positive progressive ampullary\nadenocarcinoma, as subsequent therapy for KRAS G12 mutation positive locally advanced or\nmetastatic pancreatic adenocarcinoma, for the treatment of brain metastases in KRAS G12C-\nmutated NSCLC, as subsequent therapy for KRAS G12C mutation positive recurrent NSCLC, as\nsubsequent therapy for KRAS G`12 mutation positive unresectable or resected gross residual (R2)\ndisease, or biliary tract cancer. NCCN also recommends the use of Krazati in combination with\npanitumumab or as a single agent for patients with KRAS G12C-mutated unresectable metastatic\nCRC and previous FOLFOX (fluorauracil, leucovorin, and oxaliplatin) or CapeOX (capecitabine\nand oxaliplatin), and as adjuvant, second-line and subsequent therapy in combination with\ncetuximab or panitumumab or as a single agent, if not previously given, for progression of\nadvanced or metastatic colorectal cancer, or patient is ineligible for or progressed on checkpoint\ninhibitor immunotherapy.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For mem",
    "tic colorectal cancer, or patient is ineligible for or progressed on checkpoint\ninhibitor immunotherapy.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Krazati will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-Small Cell Lung Cancer (NSCLC)\n© 2024 UnitedHealthcare Services, Inc.\n1\n1. Initial Authorization\na. Krazati will be approved based on the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n(2) Presence of KRAS G12C mutation\n-AND-\n(3) Disease is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\n-AND-\n(4) Patient has received at least one prior systemic therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Krazati will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Krazati therapy\nAuthorization will be issued for 12 months.\nC. Colorectal Cancer\n1. Initial Authorization\na. Krazati will be approved based on the following criteria:\n(1) Diagnosis of colorectal cancer\n-AND-\n(2) Presence of KRAS G12C mutation\n-AND-\n(3) Disease is one of the following:\n(a) Recurrent\n© 2024 UnitedHealthcare Services, Inc.\n2\n(b) Advanced\n(c) Metastatic\n-AND-\n(4) Patient has received at least one prior systemic therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Krazati will be approved based on the following criterion:\n(1) Patient does not show evidence of ",
    " at least one prior systemic therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Krazati will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Krazati therapy\nAuthorization will be issued for 12 months.\nD. Ampullary Adenocarcinoma\n1. Initial Authorization\na. Krazati will be approved based on the following criteria:\n(1) Diagnosis of ampullary adenocarcinoma\n-AND-\n(2) Presence of KRAS G12C mutation\n-AND-\n(3) Disease is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\n-AND-\n(4) Patient has received at least one prior systemic therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Krazati will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Krazati therapy\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n3\nE. Pancreatic Adenocarcinoma\n1. Initial Authorization\na. Krazati will be approved based on the following criteria:\n(1) Diagnosis of pancreatic adenocarcinoma\n-AND-\n(2) Presence of KRAS G12C mutation\n-AND-\n(3) Disease is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\n-AND-\n(4) Patient has received at least one prior systemic therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Krazati will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Krazati therapy\nAuthorization will be issued for 12 months.\nF. Biliary Tract Cancers\n1. Initial Authorization\na. Krazati will be approved based on the following criteria:\n(1) Diagnosis of one of the following:\n(a) Gallbladder Cancer\n(b) Intrahepatic cholangiocarcinoma\n(c) Extrahepatic cholangiocarcinoma\n-AND-\n(2) Presence of KRAS G12C mutation\n© 2024 UnitedHealthcare Services, Inc.\n4\n-AND-\n(3) Disease is one of the following:\n(a) Unresectable\n(b) Resected gross residual (R2)\n(c) Metastatic\n-AND-\n(4) Patient has received ",
    " KRAS G12C mutation\n© 2024 UnitedHealthcare Services, Inc.\n4\n-AND-\n(3) Disease is one of the following:\n(a) Unresectable\n(b) Resected gross residual (R2)\n(c) Metastatic\n-AND-\n(4) Patient has received at least one prior systemic therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Krazati will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Krazati therapy\nAuthorization will be issued for 12 months.\nG. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits and/or step therapy may be in place.\n4. References:\n1. Krazati [package insert]. San Diego, CA: Mirati Therapeutics, Inc.; June 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org. Accessed on July 10, 2024.\n© 2024 UnitedHealthcare Services, Inc.\n5\nProgram Prior Authorization/Notification – Krazati (adagrasib)\nChange Control\n2/2023 New program\n2/2024 Annual review. Added criteria for NCCN recommended use of Krazati\nin colon cancer, rectal cancer, ampullary adenocarcinoma and\npancreatic adenocarcinoma. Updated background and references.\n8/2024 Combined criteria for colon and rectal cancer in one section –\nColorectal Cancer. Added c",
    "ctal cancer, ampullary adenocarcinoma and\npancreatic adenocarcinoma. Updated background and references.\n8/2024 Combined criteria for colon and rectal cancer in one section –\nColorectal Cancer. Added criteria for NCCN recommended use of\nKrazati in biliary tract cancer. Updated background and references.\n© 2024 UnitedHealthcare Services, Inc.\n6"
  ]
}